Addus HomeCare (ADUS) PT Raised to $125 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ADUS Hot Sheet
Rating Summary:
15 Buy, 2 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Jefferies analyst Brian Tanquilut raised the price target on Addus HomeCare (NASDAQ: ADUS) to $125.00 (from $120.00) while maintaining a Buy rating.
The analyst commented, "ADUS's announcement of a $192MM all-cash acquisition of a hospice asset in Ohio is a notable positive as it should boost 2021 revenues by >$55MM and EBITDA by$10-$15MM (vs. current Street ests of $823MM and $85MM, respectively). Today'sacquisition also highlights mgmt's continued commitment to taking advantage of its strong balance sheet and robust FCF to pursue accretive and strategic, geographically-aligned acquisitions."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zimmer Biomet (ZBH) PT Raised to $120 at Jefferies
- Procore Technologies, Inc (PCOR) PT Raised to $85 at Stifel
- Camtek (CAMT) PT Lowered to $140 at Stifel
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Jefferies & Co, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
